<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="doi: 10.1186/s12916-019-1411-9 : Research Article The case for a universal" exact="hepatitis C" post="vaccine to achieve hepatitis C elimination ScottNicknick.scott@burnet.edu.au12WilsonDavid P.david.wilson@burnet.edu.au12ThompsonAlexander J.alexander.thompson@svhm.org.au34BarnesEleanorellie.barnes@ndm.ox.ac.uk56El-SayedManalmanalhelsayed@yahoo.co.uk7BenzakenAdele"/>
 <result pre="The case for a universal hepatitis C vaccine to achieve" exact="hepatitis C" post="elimination ScottNicknick.scott@burnet.edu.au12WilsonDavid P.david.wilson@burnet.edu.au12ThompsonAlexander J.alexander.thompson@svhm.org.au34BarnesEleanorellie.barnes@ndm.ox.ac.uk56El-SayedManalmanalhelsayed@yahoo.co.uk7BenzakenAdele Schwartzadelebenz@gmail.com8DrummerHeidi E.heidi.drummer@burnet.edu.au1910HellardMargaret E.margaret.hellard@burnet.edu.au121011[1], 0000 0001"/>
 <result pre="Monash University, [10], 0000 0001 2179 088Xgrid.1008.9Peter Doherty Institute for" exact="Infection" post="and Immunity, The University of Melbourne, [11], 0000 0004"/>
 <result pre="The University of Melbourne, [11], 0000 0004 0432 511Xgrid.1623.6Department of" exact="Infectious" post="Diseases, The Alfred Hospital and Monash University, epub: 2019-9-9pmc-release:"/>
 <result pre="The introduction of highly effective direct-acting antiviral (DAA) therapy for" exact="hepatitis C" post="has led to calls to eliminate it as a"/>
 <result pre="suggest it is possible to develop a vaccine to prevent" exact="hepatitis C." post="Using a mathematical model, we examined the potential impact"/>
 <result pre="a mathematical model, we examined the potential impact of a" exact="hepatitis C" post="vaccine on the feasibility and cost of achieving the"/>
 <result pre="countries (47%). Conclusions These findings strongly support the case for" exact="hepatitis C" post="vaccine development as an urgent public health need, to"/>
 <result pre="vaccine development as an urgent public health need, to ensure" exact="hepatitis C" post="elimination is achievable and at substantially reduced costs for"/>
 <result pre="supplementary material, which is available to authorized users. Keywords Elimination" exact="Hepatitis" post="C Mathematical model Vaccine Funding http://dx.doi.org/10.13039/501100000925National Health and Medical"/>
 <result pre="There are vast differences in the epidemiology and burden of" exact="hepatitis C" post="across the globe that have significant implications for meeting"/>
 <result pre="significant implications for meeting the World Health Organization (WHO) 2030" exact="hepatitis C" post="elimination targets. A consequence is that responses to hepatitis"/>
 <result pre="hepatitis C elimination targets. A consequence is that responses to" exact="hepatitis C" post="must be tailored to particular settings; major considerations include"/>
 <result pre="and human resources). The majority of high-income countries have concentrated" exact="hepatitis C" post="epidemics with transmission predominantly occurring among PWID [1â€&quot;3]. In"/>
 <result pre="occurring among PWID [1â€&quot;3]. In settings where the prevalence of" exact="hepatitis C" post="among PWID is less than approximately 50%, mathematical models"/>
 <result pre="number of European countries [5â€&quot;8]. However, if the prevalence of" exact="hepatitis C" post="among PWID is extremely high (greater than approximately 75%,"/>
 <result pre="therefore likely to need significant additional prevention measures to achieve" exact="hepatitis C" post="elimination. Many low- and middle-income countries have generalised epidemics"/>
 <result pre="elimination. Many low- and middle-income countries have generalised epidemics with" exact="disease" post="driven by iatrogenic transmission in official and unofficial health"/>
 <result pre="in addition to transmission among PWID. The prospects of reducing" exact="hepatitis C" post="incidence through treatment-as-prevention in these countries is low due"/>
 <result pre="incidence through treatment-as-prevention in these countries is low due to" exact="limited" post="financial resources and infrastructure to support rapid testing and"/>
 <result pre="sources of transmission, and minimal existing prevention interventions. Vaccines for" exact="hepatitis C" post="have been in pre-clinical development since the discovery of"/>
 <result pre="C have been in pre-clinical development since the discovery of" exact="hepatitis C" post="virus almost 30â€‰years ago. Two candidates have reached phase"/>
 <result pre="the possibility of developing a vaccine for the prevention of" exact="hepatitis C" post="within the next 5â€&quot;10â€‰years. However, vigorous research and development"/>
 <result pre="within the next 5â€&quot;10â€‰years. However, vigorous research and development of" exact="hepatitis C" post="vaccine candidates and the immunological requirements for natural protective"/>
 <result pre="of direct acting antiviral therapies (DAAs), highly effective treatments for" exact="hepatitis C." post="The global spotlight is currently focussed on the major"/>
 <result pre="the short-term, reflecting on achievements and lessons learnt in other" exact="disease" post="areas makes it hard to imagine a vaccine not"/>
 <result pre="imagine a vaccine not playing a central role in long-term" exact="hepatitis C" post="control strategies for the majority of the world. In"/>
 <result pre="In this study, we used a mathematical model to project" exact="hepatitis C" post="incidence reduction following the implementation of a variety of"/>
 <result pre="achieve the WHO elimination target of an 80% reduction in" exact="hepatitis C" post="incidence by 2030 in the most cost-effective way (as"/>
 <result pre="The analysis was performed with and without a theoretical prophylactic" exact="hepatitis C" post="vaccine, to determine if additional impact and/or cost savings"/>
 <result pre="and relative importance that a future vaccine has in achieving" exact="hepatitis C" post="elimination. Methods Model description We used a dynamic compartmental"/>
 <result pre="Methods Model description We used a dynamic compartmental model of" exact="hepatitis C" post="transmission (Fig.Â 1). The model included two population groups:"/>
 <result pre="15â€&quot;64-year-old population, as a proxy for non-PWID at risk of" exact="hepatitis C" post="infection in settings with generalised or mixed epidemics). Fig."/>
 <result pre="as a proxy for non-PWID at risk of hepatitis C" exact="infection" post="in settings with generalised or mixed epidemics). Fig. 1"/>
 <result pre="rate, with PWID having an additional injecting-specific mortality rate. The" exact="total" post="combined population size was held constant by the entry"/>
 <result pre="cease injecting and move to the general community, with the" exact="total" post="PWID population size maintained by recruitment from the general"/>
 <result pre="rather than antibody testing due to known past exposure to" exact="hepatitis C." post="Susceptible individuals could become infected according to the current"/>
 <result pre="C. Susceptible individuals could become infected according to the current" exact="hepatitis C" post="prevalence within their population group, whether or not they"/>
 <result pre="constant that allows the model to be adapted to the" exact="hepatitis C" post="prevalence in the given setting. For concentrated epidemic settings,"/>
 <result pre="prevalence in the given setting. For concentrated epidemic settings, the" exact="infection" post="constant in the general community was set to zero."/>
 <result pre="prevalence of injecting drug use [9] and the prevalence of" exact="hepatitis C" post="among PWID [9] and the general population [14, 15]"/>
 <result pre="uptake rate of injecting drug use and the force of" exact="infection" post="constants among PWID and the general community. Limited global"/>
 <result pre="force of infection constants among PWID and the general community." exact="Limited" post="global datasets were available with hepatitis C prevalence estimates,"/>
 <result pre="and the general community. Limited global datasets were available with" exact="hepatitis C" post="prevalence estimates, meaning that the models were calibrated using"/>
 <result pre="be considered to be the theoretical maximum attainable impact of" exact="hepatitis C" post="elimination programmes. By assuming high coverage of testing and"/>
 <result pre="theoretical settings that had concentrated epidemics (25%, 50% or 75%" exact="hepatitis C" post="prevalence among PWID), generalised epidemics (1%, 2%, 3%, 5%,"/>
 <result pre="epidemics (1%, 2%, 3%, 5%, 10%, 15%, 25% or 30%" exact="hepatitis C" post="prevalence among the general community) and mixed epidemics (all"/>
 <result pre="among the general community) and mixed epidemics (all combinations of" exact="hepatitis C" post="prevalence among PWID and the general community). Results for"/>
 <result pre="period (2018â€&quot;2030) This was implemented as 1/12th of people with" exact="hepatitis C" post="in the general population being diagnosed every year between"/>
 <result pre="is only half as efficacious for people after successful treatment." exact="Combined" post="testing and vaccination of the general community No vaccination"/>
 <result pre="was implemented as a relative reduction in the force of" exact="infection" post="for the fraction of PWID considered to be adequately"/>
 <result pre="sensitivity analysis â€ƒCost discounting 3% per annum WHO recommendation [16]" exact="Hepatitis" post="C-related parameters â€ƒRelative reduction in infection risk when covered"/>
 <result pre="annum WHO recommendation [16] Hepatitis C-related parameters â€ƒRelative reduction in" exact="infection" post="risk when covered by harm reduction 79% Turner et"/>
 <result pre="was not in a WHO high income classification AND the" exact="total" post="number of people living with hepatitis C was &amp;gt;â€‰5"/>
 <result pre="income classification AND the total number of people living with" exact="hepatitis C" post="was &amp;gt;â€‰5 times the total number of estimated hepatitis"/>
 <result pre="of people living with hepatitis C was &amp;gt;â€‰5 times the" exact="total" post="number of estimated hepatitis C-infected PWID. This classification was"/>
 <result pre="hepatitis C was &amp;gt;â€‰5 times the total number of estimated" exact="hepatitis" post="C-infected PWID. This classification was used as without modelling"/>
 <result pre="unable to produce the correct number of people living with" exact="hepatitis C" post="based on injecting drug use-related transmission alone. Countries with"/>
 <result pre="the national level), since their PWID populations had significantly higher" exact="hepatitis C" post="prevalence than the general community, and so the epidemics"/>
 <result pre="was taken for costs (TableÂ 2). The commodity cost of" exact="hepatitis C" post="antibody tests, RNA tests, and treatment were based on"/>
 <result pre="capita gross domestic product as a proxy for providersâ€™ wages." exact="Hepatitis" post="C testing efficiency for PWID was based on prevalence"/>
 <result pre="95 percentiles of these runs (parameters for the force of" exact="infection" post="constants, treatment efficacy, costs, rates of retention in care,"/>
 <result pre="fileÂ 1: Appendix Eâ€&quot;Table S7). The median relative reduction in" exact="hepatitis C" post="incidence in the optimal strategies without a vaccine was"/>
 <result pre="epidemics, the price point for a vaccine to reduce the" exact="total" post="cost of the optimal strategy was a median US$247"/>
 <result pre="epidemics, the price point for a vaccine to reduce the" exact="total" post="cost of the optimal strategy was a median US$1.36"/>
 <result pre="fileÂ 1: Appendix Eâ€&quot;Table S7). The price point was much" exact="lower" post="for settings with mixed epidemics because the vaccine needed"/>
 <result pre="impact of a vaccine on the feasibility and cost of" exact="hepatitis C" post="elimination. Total cases averted 2018â€&quot;2030 using the optimal incidence"/>
 <result pre="vaccine on the feasibility and cost of hepatitis C elimination." exact="Total" post="cases averted 2018â€&quot;2030 using the optimal incidence reduction strategies"/>
 <result pre="a component of the optimal strategy (bottom right); and the" exact="total" post="reduction in the cost of elimination if it were"/>
 <result pre="among PWID. Common to these countries is a very high" exact="hepatitis C" post="prevalence among PWID (&amp;gt;â€‰80%). The extremely high prevalence in"/>
 <result pre="meant that there were not many uninfected PWID, and so" exact="hepatitis C" post="incidence was low. Scaling up treatment led to an"/>
 <result pre="vaccines can play an important role in the elimination of" exact="hepatitis C." post="We found that for the majority of settings, the"/>
 <result pre="of settings, the WHO target of an 80% reduction in" exact="hepatitis C" post="incidence by 2030 is unlikely to be achieved without"/>
 <result pre="be achieved without additional prevention measures. Integrating a vaccine within" exact="hepatitis C" post="testing and treatment programmes could greatly improve the feasibility"/>
 <result pre="fewer than 29% of countries analysed were able to reduce" exact="hepatitis C" post="incidence by 80% by 2030 in the model (Additional"/>
 <result pre="treatment programmes have the potential to produce major gains towards" exact="hepatitis C" post="elimination, they have limitations that will require additional intervention,"/>
 <result pre="they have limitations that will require additional intervention, and a" exact="hepatitis C" post="vaccine is worth pursuing to fill this gap. A"/>
 <result pre="developed countries, a vaccine could significantly reduce the costs of" exact="hepatitis C" post="elimination. When a vaccine was modelled at US$200 per"/>
 <result pre="concentrated and mixed epidemic settings, respectively. Therefore, a vaccine for" exact="hepatitis C" post="must be cheap and simple to manufacture so that"/>
 <result pre="and also by country [26]. For example, the Centre for" exact="Disease" post="Control in the USA prices adult vaccines for hepatitis"/>
 <result pre="example, the Centre for Disease Control in the USA prices" exact="adult" post="vaccines for hepatitis B at US$30.81; human papillomavirus at"/>
 <result pre="for Disease Control in the USA prices adult vaccines for" exact="hepatitis" post="B at US$30.81; human papillomavirus at US$144.18; measles, mumps,"/>
 <result pre="B at US$30.81; human papillomavirus at US$144.18; measles, mumps, and" exact="rubella" post="at US$45.65; and varicella at US$77.57 [27]. However, in"/>
 <result pre="at US$77.57 [27]. However, in low- and middle-income countries, the" exact="hepatitis" post="B vaccine can cost as little as US$0.16 per"/>
 <result pre="additional prevention measures, the optimal global incidence reduction strategy for" exact="hepatitis C" post="is to implement targeted test and treat programmes among"/>
 <result pre="test and treat programmes among those at high risk of" exact="hepatitis C" post="infection and to implement hepatitis C vaccination through these"/>
 <result pre="treat programmes among those at high risk of hepatitis C" exact="infection" post="and to implement hepatitis C vaccination through these programmes."/>
 <result pre="at high risk of hepatitis C infection and to implement" exact="hepatitis C" post="vaccination through these programmes. It is estimated that only"/>
 <result pre="programmes. It is estimated that only 20% of people with" exact="hepatitis C" post="were diagnosed globally in 2015 [22], meaning that broad"/>
 <result pre="It is therefore worth examining the potential to combine a" exact="hepatitis C" post="vaccine with other vaccines targeting this age group such"/>
 <result pre="vaccines targeting this age group such as human papillomavirus or" exact="hepatitis" post="B. Harm reduction for PWID has an important role"/>
 <result pre="for PWID has an important role to play in the" exact="hepatitis C" post="elimination agenda. In sensitivity analyses, we tested the impact"/>
 <result pre="and opioid substitution therapy should be considered essential components of" exact="viral hepatitis" post="strategies as recommended by the WHO [29]. The total"/>
 <result pre="opioid substitution therapy should be considered essential components of viral" exact="hepatitis" post="strategies as recommended by the WHO [29]. The total"/>
 <result pre="viral hepatitis strategies as recommended by the WHO [29]. The" exact="total" post="cost of reaching the WHO hepatitis C elimination targets"/>
 <result pre="the WHO [29]. The total cost of reaching the WHO" exact="hepatitis C" post="elimination targets has been estimated at US$51 billion globally"/>
 <result pre="globally [30]. For many countries, the direct costs associated with" exact="hepatitis C" post="are currently low, because there are no or limited"/>
 <result pre="hepatitis C are currently low, because there are no or" exact="limited" post="services available to manage hepatitis C-related liver disease. As"/>
 <result pre="because there are no or limited services available to manage" exact="hepatitis" post="C-related liver disease. As a result, the required outlay"/>
 <result pre="are no or limited services available to manage hepatitis C-related" exact="liver disease." post="As a result, the required outlay on hepatitis C"/>
 <result pre="C-related liver disease. As a result, the required outlay on" exact="hepatitis C" post="testing and treatment programmes represents new costs with minimal"/>
 <result pre="direct economic benefits. However, when the indirect economic benefits of" exact="hepatitis C" post="elimination are considered, such as a larger and more"/>
 <result pre="other programmes as a way to improve prevention and reduce" exact="hepatitis C" post="transmissionâ€&quot;only one component of hepatitis C eliminationâ€&quot;and the vaccine"/>
 <result pre="improve prevention and reduce hepatitis C transmissionâ€&quot;only one component of" exact="hepatitis C" post="eliminationâ€&quot;and the vaccine was modelled to be delivered through"/>
 <result pre="treatment programmes because they will also be required to reduce" exact="hepatitis C" post="morbidity and mortality. Our estimate that a US$200 per"/>
 <result pre="be interpreted as approximately a 15% reduction in the estimated" exact="total" post="cost, should financing be obtained for hepatitis C elimination."/>
 <result pre="in the estimated total cost, should financing be obtained for" exact="hepatitis C" post="elimination. The total cost of developing a vaccine from"/>
 <result pre="cost, should financing be obtained for hepatitis C elimination. The" exact="total" post="cost of developing a vaccine from discovery through to"/>
 <result pre="of the first phase II efficacy trial of a prophylactic" exact="hepatitis C" post="vaccine designed to generate cellular immunity, released in 2019,"/>
 <result pre="this study, it is a reminder that a vaccine for" exact="hepatitis C" post="will still require significant research and development investment. By"/>
 <result pre="with 28 past and current phase II trials [32]. For" exact="hepatitis C," post="the market size of a vaccine will be determined"/>
 <result pre="DAAs to underpin global elimination efforts is blocking interest in" exact="hepatitis C" post="vaccine development. Like almost all vaccines, a public-private partnership"/>
 <result pre="this study relate to the hypothetical vaccine. Prophylactic vaccines for" exact="hepatitis C" post="are currently undergoing clinical trials, and their final properties"/>
 <result pre="if the immune system is fully restored after attaining DAA-mediated" exact="viral" post="clearance and is responsive to hepatitis C vaccination. However,"/>
 <result pre="restored after attaining DAA-mediated viral clearance and is responsive to" exact="hepatitis C" post="vaccination. However, our sensitivity analysis suggests that vaccine efficacy"/>
 <result pre="vaccination. However, our sensitivity analysis suggests that vaccine efficacy post" exact="viral" post="clearance does not change the optimal strategy and has"/>
 <result pre="costs could be avoided by inclusion with human papillomavirus or" exact="hepatitis" post="B vaccine schedules. When a vaccine is available, it"/>
 <result pre="doses or people opting out of vaccination (corresponding to the" exact="lower" post="bounds of error bars). In each of these cases,"/>
 <result pre="of different implementation strategies against various willingness-to-pay thresholds. Instead, the" exact="primary" post="aim of this study was to generate evidence that"/>
 <result pre="this study was to generate evidence that a vaccine for" exact="hepatitis C" post="has the potential to unlock health and economic benefits"/>
 <result pre="stabilised treatment. Conclusion These findings strongly support the case for" exact="hepatitis C" post="vaccine development as an urgent public health need, to"/>
 <result pre="vaccine development as an urgent public health need, to ensure" exact="hepatitis C" post="elimination is achievable and at substantially reduced costs for"/>
 <result pre="Appendix A. country specific data inputs (population sizes, prevalence of" exact="hepatitis C" post="among PWID and the general community, and staff costs);"/>
 <result pre="settings (results from concentrated, generalised and mixed epidemic settings, with" exact="hepatitis C" post="prevalence of 25/50/75% among PWID +/âˆ’â€‰1/2/3/5/10/15/20/25/30% among the general"/>
 <result pre="funding to her institution from GSK to deliver studies in" exact="hepatitis C" post="vaccines that encode class II invariant chain. MH and"/>
 <result pre="Gilead Sciences, AbbVie, and BMS. References References 1.ShepardCWFinelliLAlterMJGlobal epidemiology of" exact="hepatitis C" post="virus infectionLancet Infect Dis20055955856710.1016/S1473-3099(05)70216-416122679 2.HajarizadehBGrebelyJDoreGJEpidemiology and natural history of"/>
 <result pre="of HCV infectionNat Rev Gastroenterol Hepatol201310955356210.1038/nrgastro.2013.10723817321 3.NelsonPKMathersBMCowieBHaganHDes JarlaisDHoryniakDDegenhardtLGlobal epidemiology of" exact="hepatitis" post="B and hepatitis C in people who inject drugs:"/>
 <result pre="Rev Gastroenterol Hepatol201310955356210.1038/nrgastro.2013.10723817321 3.NelsonPKMathersBMCowieBHaganHDes JarlaisDHoryniakDDegenhardtLGlobal epidemiology of hepatitis B and" exact="hepatitis C" post="in people who inject drugs: results of systematic reviewsLancet2011378979157158310.1016/S0140-6736(11)61097-021802134"/>
 <result pre="in people who inject drugs: results of systematic reviewsLancet2011378979157158310.1016/S0140-6736(11)61097-021802134 4.ScottNSacks-DavisRPedranaADoyleJThompsonAHellardMEliminating" exact="hepatitis" post="C: the importance of frequent testing of people who"/>
 <result pre="testing of people who inject drugs in high prevalence settingsJ" exact="Viral" post="Hepat201825121472148010.1111/jvh.1297530047625 5.ScottNMcBrydeEThompsonADoyleJHellardMTreatment scale-up to achieve global HCV incidence and"/>
 <result pre="HCV incidence and mortality elimination targets: a cost-effectiveness modelGut20176681507151510.1136/gutjnl-2016-31150427196586 6.ScottNDoyleJWilsonDPWadeAHowellJPedranaAThompsonAHellardMReaching" exact="hepatitis C" post="virus elimination targets requires health system interventions to enhance"/>
 <result pre="who inject drugs in EuropeJ Hepatol20186840241110.1016/j.jhep.2017.10.01029080808 8.ScottNÃ&quot;lafssonSGottfreÃ°ssonMTyrfingssonTRÃºnarsdÃ³ttirVHansdottirIHernandezUBSigmundsdÃ³ttirGHellardMModelling the elimination of" exact="hepatitis C" post="as a public health threat in Iceland: a goal"/>
 <result pre="identifier NCT01436357. from: https://www.clinicaltrials.gov/ct2/show/study/NCT01436357. 2019. Accessed 13 June 2019 12.MicallefJMKaldorJMDoreGJSpontaneous" exact="viral" post="clearance following acute hepatitis C infection: a systematic review"/>
 <result pre="https://www.clinicaltrials.gov/ct2/show/study/NCT01436357. 2019. Accessed 13 June 2019 12.MicallefJMKaldorJMDoreGJSpontaneous viral clearance following" exact="acute" post="hepatitis C infection: a systematic review of longitudinal studiesJ"/>
 <result pre="2019. Accessed 13 June 2019 12.MicallefJMKaldorJMDoreGJSpontaneous viral clearance following acute" exact="hepatitis C" post="infection: a systematic review of longitudinal studiesJ Viral Hepat2006131344110.1111/j.1365-2893.2005.00651.x16364080"/>
 <result pre="acute hepatitis C infection: a systematic review of longitudinal studiesJ" exact="Viral" post="Hepat2006131344110.1111/j.1365-2893.2005.00651.x16364080 13.UN Population Division: from: http://www.un.org/en/development/desa/population/. 2018. Accessed 1"/>
 <result pre="Accessed 1 May 2018 14.BlachSZeuzemSMannsMAltraifIDubergA-SMuljonoDHWakedIAlavianSMLeeM-HNegroFGlobal prevalence and genotype distribution of" exact="hepatitis C" post="virus infection in 2015: a modelling studyLancet Gastroenterol Hepatol20172316117610.1016/S2468-1253(16)30181-928404132"/>
 <result pre="May 2018 14.BlachSZeuzemSMannsMAltraifIDubergA-SMuljonoDHWakedIAlavianSMLeeM-HNegroFGlobal prevalence and genotype distribution of hepatitis C" exact="virus infection" post="in 2015: a modelling studyLancet Gastroenterol Hepatol20172316117610.1016/S2468-1253(16)30181-928404132 15.GowerEEstesCBlachSRazavi-ShearerKRazaviHGlobal epidemiology"/>
 <result pre="2018 14.BlachSZeuzemSMannsMAltraifIDubergA-SMuljonoDHWakedIAlavianSMLeeM-HNegroFGlobal prevalence and genotype distribution of hepatitis C virus" exact="infection" post="in 2015: a modelling studyLancet Gastroenterol Hepatol20172316117610.1016/S2468-1253(16)30181-928404132 15.GowerEEstesCBlachSRazavi-ShearerKRazaviHGlobal epidemiology"/>
 <result pre="studyLancet Gastroenterol Hepatol20172316117610.1016/S2468-1253(16)30181-928404132 15.GowerEEstesCBlachSRazavi-ShearerKRazaviHGlobal epidemiology and genotype distribution of the" exact="hepatitis C" post="virus infectionJ Hepatol2014611 SupplS45S5710.1016/j.jhep.2014.07.02725086286 16.collab: World Health OrganizationDisability weights,"/>
 <result pre="syringe provision and opiate substitution therapy on the incidence of" exact="hepatitis C" post="virus in injecting drug users: pooling of UK evidenceAddiction2011106111978198810.1111/j.1360-0443.2011.03515.x21615585"/>
 <result pre="ribavirin in treatment-naive and previously treated patients with genotype 1" exact="hepatitis C" post="virus infection (LONESTAR): an open-label, randomised, phase 2 trialLancet2014383991651552310.1016/S0140-6736(13)62121-224209977"/>
 <result pre="treatment-naive and previously treated patients with genotype 1 hepatitis C" exact="virus infection" post="(LONESTAR): an open-label, randomised, phase 2 trialLancet2014383991651552310.1016/S0140-6736(13)62121-224209977 19.GaneEJStedmanCAHylandRHSorensenRDSymondsWTHindesRBerreyMMOnce daily"/>
 <result pre="and previously treated patients with genotype 1 hepatitis C virus" exact="infection" post="(LONESTAR): an open-label, randomised, phase 2 trialLancet2014383991651552310.1016/S0140-6736(13)62121-224209977 19.GaneEJStedmanCAHylandRHSorensenRDSymondsWTHindesRBerreyMMOnce daily"/>
 <result pre="19.GaneEJStedmanCAHylandRHSorensenRDSymondsWTHindesRBerreyMMOnce daily PSI-7977 plus RBV: pegylated interferon-alfa not required for" exact="complete" post="rapid viral response in treatment-naive patients with HCV GT2"/>
 <result pre="PSI-7977 plus RBV: pegylated interferon-alfa not required for complete rapid" exact="viral" post="response in treatment-naive patients with HCV GT2 or GT3Hepatology:"/>
 <result pre="20.PoordadFredLawitzEricKowdleyKris V.CohenDaniel E.PodsadeckiThomasSiggelkowSaraHeckamanMicheleLarsenLoisMenonRajeevKoevGennadiyTripathiRakeshPilot-MatiasTamiBernsteinBarryExploratory Study of Oral Combination Antiviral Therapy for" exact="Hepatitis" post="CNew England Journal of Medicine20133681455310.1056/NEJMoa120880923281975 21.GaneEJStedmanCAHylandRHDingXSvarovskaiaESubramanianGMSymondsWTMcHutchisonJGPangPSEfficacy of nucleotide polymerase"/>
 <result pre="against HCV genotype 1 infectionGastroenterology20141463736743. e73110.1053/j.gastro.2013.11.00724262278 22.World Health Organization: Global" exact="Hepatitis" post="Report 2017. Geneva. Licence: CC BY-NC-SA 3.0 IGO. 2017."/>
 <result pre="World Health OrganizationReview of vaccine price data2013 27.collab: Centre for" exact="Disease" post="ControlCDC vaccine price list2018 28.GountasISypsaVBlachSRazaviHHatzakisAHCV elimination among people WHO"/>
 <result pre="eraPLoS One2018138e020210910.1371/journal.pone.020210930114207 29.collab: World Health OrganizationGlobal health sector strategy on" exact="viral hepatitis" post="2016â€&quot;20212016 30.Pedrana A, Howell J, SchrÃ¶der S, Scott N,"/>
 <result pre="One2018138e020210910.1371/journal.pone.020210930114207 29.collab: World Health OrganizationGlobal health sector strategy on viral" exact="hepatitis" post="2016â€&quot;20212016 30.Pedrana A, Howell J, SchrÃ¶der S, Scott N,"/>
 <result pre="N, Wilson D, Kuschel C, Aufegger L, M. H: Eliminating" exact="viral" post="hepatitis: the investment case. Doha, Qatar: World Innovation Summit"/>
</results>
